Ultragenyx Pharmaceutical (RARE) Non Operating Income (2013 - 2017)

Ultragenyx Pharmaceutical (RARE) has 5 years of Non Operating Income data on file, last reported at $4.5 million in Q3 2017.

• On a quarterly basis, Non Operating Income rose 412.56% year-over-year to $4.5 million in Q3 2017; TTM through Sep 2017 was $11.0 million, a 189.18% increase from a year earlier, with the FY2016 full-year figure at $2.2 million, up 2.26% from the prior year.
• Non Operating Income for Q3 2017 stood at $4.5 million, down from $5.6 million in the prior quarter.
• Over the last five years, Non Operating Income for RARE reached as high as $5.6 million in Q2 2017 and fell as low as -$3.3 million in Q1 2014.
• Historically, Non Operating Income has averaged $619000.0 across 5 years, with a median of $355000.0 in 2015.
• Across the five-year window, Non Operating Income surged 5128.57% in 2015 and slumped 174.95% in 2016, its largest moves.
• Year by year, Non Operating Income stood at -$1.8 million in 2013, then jumped by 111.44% to $205000.0 in 2014, then jumped by 357.56% to $938000.0 in 2015, then sank by 174.95% to -$703000.0 in 2016, then jumped by 738.69% to $4.5 million in 2017.
• Per Business Quant data, the three most recent Non Operating Income figures were $4.5 million in Q3 2017, $5.6 million in Q2 2017, and $1.7 million in Q1 2017.